European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2022, Volume and Issue: 50(4), P. 1270 - 1272
Published: Dec. 6, 2022
Language: Английский
Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)
Published: Aug. 28, 2023
Abstract Microglial activation plays central roles in neuroinflammatory and neurodegenerative diseases. Positron emission tomography (PET) targeting 18 kDa Translocator Protein (TSPO) is widely used for localising inflammation vivo, but its quantitative interpretation remains uncertain. We show that TSPO expression increases activated microglia mouse brain disease models does not change a non-human primate model or common human describe genetic divergence the gene promoter, consistent with hypothesis increase myeloid cells depends on transcription factor AP1 unique to subset of rodent species within Muroidea superfamily. Finally, we identify LCP2 TFEC as potential markers microglial humans. These data emphasise related different phenomena than mice, TSPO-PET signals humans reflect density inflammatory rather state.
Language: Английский
Citations
89
The Lancet Oncology, Journal Year: 2024, Volume and Issue: 25(1), P. e29 - e41
Published: Jan. 1, 2024
Language: Английский
Citations
58
Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)
Published: Jan. 2, 2025
Abstract Radiopharmaceuticals involve the local delivery of radionuclides to targeted lesions for diagnosis and treatment multiple diseases. Radiopharmaceutical therapy, which directly causes systematic irreparable damage cells, has attracted increasing attention in refractory diseases that are not sensitive current therapies. As Food Drug Administration (FDA) approvals [ 177 Lu]Lu-DOTA-TATE, Lu]Lu-PSMA-617 their complementary diagnostic agents, namely, 68 Ga]Ga-DOTA-TATE Ga]Ga-PSMA-11, radiopharmaceutical-based theranostics (radiotheranostics) being increasingly implemented clinical practice oncology, lead a new era radiopharmaceuticals. The generation radiopharmaceuticals utilizes targeting vector achieve accurate avoid off-target deposition, making it possible improve efficiency biosafety tumour therapy. Numerous studies have focused on developing novel broader range disease targets, demonstrating remarkable vivo performance. These include high tumor uptake, prolonged retention time, favorable pharmacokinetic properties align with standards. While radiotheranostics been widely applied applications now expanding neurodegenerative diseases, cardiovascular inflammation. Furthermore, radiotheranostic-empowered precision medicine is revolutionizing cancer paradigm. Diagnostic play pivotal role patient stratification planning, leading improved therapeutic outcomes radionuclide This review offers comprehensive overview evolution radiopharmaceuticals, including both FDA-approved clinically investigated explores mechanisms cell death induced by It emphasizes significance future prospects theranostic-based advancing medicine.
Language: Английский
Citations
7
Cancers, Journal Year: 2024, Volume and Issue: 16(9), P. 1715 - 1715
Published: April 28, 2024
Gliomas represent the most commonly occurring tumors in central nervous system and account for approximately 80% of all malignant primary brain tumors. With a high malignancy recurrence risk, prognosis high-grade gliomas is poor, with mean survival time 12–18 months. While contrast-enhanced MRI serves as standard diagnostic imaging modality gliomas, it faces limitations evaluation recurrent failing to distinguish between treatment-related changes tumor progression, offers no direct therapeutic options. Recent advances modalities have attempted address some these limitations, including positron emission tomography (PET), which has demonstrated success delineating margins guiding treatment gliomas. Additionally, advent theranostics nuclear medicine, PET tracers, when combined agents, also evolved beyond purely modality, serving both roles. This review will discuss growing involvement diagnosing treating associated impact on quality life functional recovery.
Language: Английский
Citations
10
European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2024, Volume and Issue: 51(8), P. 2371 - 2381
Published: Feb. 24, 2024
According to the World Health Organization classification for tumors of central nervous system, mutation status isocitrate dehydrogenase (IDH) genes has become a major diagnostic discriminator gliomas. Therefore, imaging-based prediction IDH is high interest individual patient management. We compared and evaluated value radiomics derived from dual positron emission tomography (PET) magnetic resonance imaging (MRI) data predict non-invasively.
Language: Английский
Citations
5
Seminars in Nuclear Medicine, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 1, 2024
Language: Английский
Citations
5
Journal of Nuclear Medicine, Journal Year: 2023, Volume and Issue: 64(10), P. 1519 - 1525
Published: Aug. 3, 2023
The 18-kDa translocator protein (TSPO) is gaining recognition as a relevant target in glioblastoma imaging. However, data on the potential prognostic value of TSPO PET imaging are lacking. Therefore, we investigated association results with survival outcome homogeneous cohort patients. Methods: Patients were included who had newly diagnosed, histologically confirmed isocitrate dehydrogenase (IDH)-wild-type available before either normofractionated radiotherapy combined temozolomide or hypofractionated radiotherapy. SUVmax PET, binding affinity status, tumor volumes MRI, and further clinical data, such O6-alkylguanine DNA methyltransferase (MGMT) telomerase reverse transcriptase (TERT) gene promoter mutation correlated patient survival. Results: Forty-five patients (median age, 63.3 y) included. Median was 2.2 (range, 1.0-4.7). A signal associated survival: High uptake intensity (SUVmax > 2.2) related to significantly shorter overall (OS; 8.3 vs. 17.8 mo, P = 0.037). Besides SUVmax, factors for OS age (P 0.046), MGMT methylation status 0.032), T2-weighted MRI volume 0.031). In multivariate analysis, remained an independent factor 0.023), hazard ratio 2.212 (95% CI, 1.115-4.386) death cases high 2.2). Conclusion: diagnosed IDH-wild-type glioblastoma. seems add insights beyond established parameters might serve informative tool clinicians make predictions
Language: Английский
Citations
11
Diagnostics, Journal Year: 2023, Volume and Issue: 13(10), P. 1813 - 1813
Published: May 21, 2023
Our aim was to provide a comprehensive overview of the existing literature concerning clinical applications positron emission computed tomography (PET) with radiopharmaceuticals targeting translocator protein (TSPO) in gliomas. A search for studies about TSPO PET last 10 years (from 2013 February 2023) carried out on PubMed, Scopus, and Web Science using following keywords: “PET” AND “Gliomas” “TSPO”. The Critical Appraisal Skills Program checklist diagnostic test used testing quality selected papers. Ten articles were selected, encompassing 314 glioma patients submitted PET/CT (9/10) or PET/MRI (1/10) ligands. Among various available tracers, most frequently third-generation ligand, [18F]-GE-180. results useful identify anaplastic transformation gliomas prognostic stratification bearing homogeneous genetic alterations. When compared amino-acid PET, [18F]-GE-180 presented superior image provided larger only partially overlapping PET-based volumes. Although biased by some issues (i.e., small sample size, coming from same country), preliminary encouraging. Further are needed define implications practice shape role patients’ selection potential TSPO-targeted molecular therapies.
Language: Английский
Citations
10
Science Advances, Journal Year: 2023, Volume and Issue: 9(43)
Published: Oct. 27, 2023
Various cellular sources hamper interpretation of positron emission tomography (PET) biomarkers in the tumor microenvironment (TME). We developed an approach immunomagnetic cell sorting after vivo radiotracer injection (scRadiotracing) with three-dimensional (3D) histology to dissect allocation PET signals TME. In mice implanted glioblastoma, translocator protein (TSPO) uptake per was higher compared tumor-associated microglia/macrophages (TAMs), validated by levels. Translation vitro scRadiotracing patients glioma immediately resection confirmed single-cell TSPO tracer cells immune cells. Across species, explained heterogeneity individual TSPO-PET signals. consideration and type abundance, were main contributor enrichment glioblastoma; however, proteomics identified potential targets highly specific for TAMs. Combining measures 3D facilitates precise serves validate emerging novel TAM-specific radioligands.
Language: Английский
Citations
10
Expert Review of Anticancer Therapy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 22
Published: April 5, 2025
The World Health Organization's 2021 classification of central nervous system neoplasms incorporated molecular and genetic features for classifying gliomas. Classification gliomas located in deep-seated structures became a clinical conundrum given the absence crucial pathological data. Advances noninvasive imaging modalities offered virtual biopsy as novel solution to this problem by identifying surrogate radiomic signatures. Liquid biopsies blood or cerebrospinal fluid provided another enormous opportunity genomic, metabolomic proteomic We summarize appraise current state evidence with regards liquid care patients PubMed, Embase Google Scholar were searched on 7/30/2024 relevant articles published after year 2013 English language. A large body preclinical preliminary suggests that is possible combined use multiple conjunction machine learning radiomics. Likewise, focused ultrasound may be valuable tool obtain genomic data regarding glioma minimally invasive manner. These will likely become an integral part future.
Language: Английский
Citations
0